S&P 500
(-0.21%) 5 000.82 points
Dow Jones
(0.49%) 37 961 points
Nasdaq
(-0.91%) 15 459 points
Oil
(0.31%) $82.99
Gas
(2.22%) $1.796
Gold
(0.28%) $2 404.80
Silver
(0.69%) $28.58
Platinum
(-1.17%) $943.30
USD/EUR
(-0.29%) $0.937
USD/NOK
(-0.50%) $10.99
USD/GBP
(-0.19%) $0.802
USD/RUB
(-0.81%) $93.14

Realtime updates for CombiGene AB (publ) [COMBI.ST]

Exchange: STO Sector: Healthcare Industry: Biotechnology
Last Updated19 Apr 2024 @ 10:22

0.00% SEK 3.85

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 10:22):

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy...

Stats
Today's Volume 34 959.00
Average Volume 56 130.00
Market Cap 76.23M
EPS SEK-0.424 ( 2023-09-30 )
Last Dividend SEK0 ( N/A )
Next Dividend SEK0 ( N/A )
P/E -1.850
ATR14 SEK0.0540 (1.40%)

CombiGene AB (publ) Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CombiGene AB (publ) Financials

Annual 2023
Revenue: SEK5.54M
Gross Profit: SEK-38.78M (-699.55 %)
EPS: SEK-1.800
Q4 2023
Revenue: SEK596 000
Gross Profit: SEK-8.89M (-1 492.11 %)
EPS: SEK-0.320
Q3 2023
Revenue: SEK1.17M
Gross Profit: SEK-8.27M (-710.13 %)
EPS: SEK-0.420
Q2 2023
Revenue: SEK1.79M
Gross Profit: SEK-7.70M (-430.59 %)
EPS: SEK-0.320

Financial Reports:

No articles found.

CombiGene AB (publ)

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators